Cellectis S.A. (CLLS) vs Organigram Global (OGI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Organigram Global (OGI) has outperformed Cellectis S.A. (CLLS) over the past year, losing 51.0% versus a loss of 64.9%. Over five years, CLLS leads with a -87.6% price change compared with -89.3% for OGI. Organigram Global is the larger company by market cap ($138.4 million vs $135.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CLLS | OGI |
|---|---|---|
| Share price | $1.34 | $0.96 |
| Market cap | $134.96M | $138.39M |
| 1-day change | -4.29% | -1.04% |
| YTD return | -72.31% | -42.86% |
| 1-year return | -64.92% | -51.02% |
| 5-year return | -87.63% | -89.29% |
| P/E ratio (TTM) | — | 2.23 |
| Forward P/E | — | 40.00 |
| EPS (TTM) | $-0.64 | $0.43 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.48 | $2.24 |
| 52-week low | $1.25 | $0.853 |
| Distance from 52-week high | -75.55% | -57.14% |
| Analyst consensus | none | buy |
| Avg. price target upside | +297.76% | — |
| Average volume | 78.85K | 891.72K |
| Shares outstanding | 72.72M | 144.15M |
| Employees | 224 | 1,139 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Drug Manufacturers - Specialty & Generic |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- OGI has outperformed CLLS by 13.9 percentage points over the past year.
About Cellectis S.A.
CLLS stock →Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of lasme-cel in patients with r/r ALL; NatHaLi-01, designed to evaluate the safety, expansion, persistence, and clinical activity of eti-cel in patients with relapsed or refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL).
Healthcare · Biotechnology · 224 employees
About Organigram Global
OGI stock →Organigram Global Inc. engages in the production and sale of cannabis and cannabis-derived products in Canada.
Healthcare · Drug Manufacturers - Specialty & Generic · 1,139 employees
CLLS vs OGI FAQ
Which is bigger, Cellectis S.A. or Organigram Global?
Organigram Global (OGI) is larger, with a market capitalization of $138.39M compared with $134.96M for Cellectis S.A. (CLLS).
Which stock has performed better over the past year, CLLS or OGI?
OGI returned -51.02% over the past 12 months, compared with -64.92% for CLLS (price return, excluding dividends). Past performance does not predict future results.
Are Cellectis S.A. and Organigram Global in the same industry?
Both are in the Healthcare sector, but in different industries: Biotechnology for Cellectis S.A. and Drug Manufacturers - Specialty & Generic for Organigram Global.